Small molecule anticancer drugs approved during 2021-2022: Synthesis and clinical applications

被引：5

作者：

Tamatam, Rekha ^{[1
]}

Mohammed, Arifullah ^{[1
]}

机构：

[1] Univ Malaysia Kelantan, Fac Agro Based Ind, Dept Agr Sci, Jeli 17600, Kelantan, Malaysia

来源：

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY | 2024年 / 272卷

关键词：

FDA; New drugs; Synthesis; Clinical applications; Oncology; Small molecules; CHRONIC MYELOID-LEUKEMIA; ENDOTHELIAL GROWTH-FACTOR; KINASE DOMAIN MUTATIONS; CELL LUNG-CANCER; SINGLE-ARM; PHASE-II; INHIBITOR; ABL; POTENT; FDA;

D O I：

10.1016/j.ejmech.2024.116441

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Drugs have structural homology across similar biological targets. Small molecule drugs have the efficacy to target specific molecular targets within the cancer cells with enhanced cell membrane permeability, oral administration, selectivity, and specific affinity. The objective of this review is to highlight the clinical importance and synthetic routes of new small molecule oncology drugs approved by the FDA during the period 2021-2022. These marketed drugs are listed based on the month and year of approval in chronological order. We believed that an in-depth insight into the synthetic approaches for the construction of these chemical entities would enhance the ability to develop new drugs more efficiently.

引用

页数：25

共 138 条

[1] Trilaciclib and the economic value of multilineage myeloprotection from chemotherapy-induced myelosuppression among patients with extensive-stage small cell lung cancer treated with first-line chemotherapy [J].

Abraham, Ivo ;

Onyekwere, Uchenna ;

Deniz, Baris ;

Moran, Donald ;

Chioda, Marc ;

MacDonald, Karen ;

Huang, Huan .

JOURNAL OF MEDICAL ECONOMICS, 2021, 24 :71-83

[2]

Amgen Inc, 2021, LUMAKRASTM (sotorasib) tablets, for oral use: US prescribing information

[3]

[Anonymous], 2023, Med. Lett. Drugs Ther., V65, P69

[4]

[Anonymous], 2023, Med. Lett. Drugs Ther., V65, P58

[5]

[Anonymous], 2022, Novel Drug Approvals for 2022

[6] MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression [J].

Awad, Mark M. ;

Oxnard, Geoffrey R. ;

Jackman, David M. ;

Savukoski, Daniel O. ;

Hall, Dimity ;

Shivdasani, Priyanka ;

Heng, Jennifer C. ;

Dahlberg, Suzanne E. ;

Anne, Pasi A. J. ;

Verma, Suman ;

Christensen, James ;

Hammerman, Peter S. ;

Sholl, Lynette M. .

JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (07) :721-+

[7] Novel drugs targeting EGFR and HER2 exon 20 mutations in metastatic NSCLC [J].

Baraibar, Iosune ;

Mezquita, Laura ;

Gil-Bazo, Ignacio ;

Planchard, David .

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2020, 148

[8] Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer [J].

Benesova, Martina ;

Schaefer, Martin ;

Bauder-Wuest, Ulrike ;

Afshar-Oromieh, Ali ;

Kratochwil, Clemens ;

Mier, Walter ;

Haberkorn, Uwe ;

Kopka, Klaus ;

Eder, Matthias .

JOURNAL OF NUCLEAR MEDICINE, 2015, 56 (06) :914-920

[9] First-in-human, phase I/IIa clinical study of the peptidase potentiated alkylator melflufen administered every three weeks to patients with advanced solid tumor malignancies [J].

Berglund, Ake ;

Ullen, Anders ;

Lisyanskaya, Alla ;

Orlov, Sergey ;

Hagberg, Hans ;

Tholander, Bengt ;

Lewensohn, Rolf ;

Nygren, Peter ;

Spira, Jack ;

Harmenberg, Johan ;

Jerling, Markus ;

Alvfors, Carina ;

Ringbom, Magnus ;

Nordstrom, Eva ;

Soderlind, Karin ;

Gullbo, Joachim .

INVESTIGATIONAL NEW DRUGS, 2015, 33 (06) :1232-1241

[10] Preclinical Characterization of G1T28: A Novel CDK4/6 Inhibitor for Reduction of Chemotherapy-Induced Myelosuppression [J].

Bisi, John E. ;

Sorrentino, Jessica A. ;

Roberts, Patrick J. ;

Tavares, Francis X. ;

Strum, Jay C. .

MOLECULAR CANCER THERAPEUTICS, 2016, 15 (05) :783-793

← 1 2 3 4 5 6 7 8 9 10 →